IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity - Wikidata - wikimedia - TriplyDB

IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity

IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity

http://www.wikidata.org/entity/Q37413874

about

Mechanisms behind functional avidity maturation in T cells Therapeutic cancer vaccines: past, present, and future Overlapping, additive and counterregulatory effects of type II and I interferons on myeloid dendritic cell functions ChemR23 dampens lung inflammation and enhances anti-viral immunity in a mouse model of acute viral pneumonia Adjuvants for peptide-based cancer vaccines The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.Inflammatory cytokines as a third signal for T cell activation Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types.Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.Out-of-sequence signal 3 as a mechanism for virus-induced immune suppression of CD8 T cell responses.Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9 Host STAT2/type I interferon axis controls tumor growth.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.The immune response to tumors as a tool toward immunotherapy.Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy Cell-intrinsic role for IFN-α-STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response.Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity Exploiting antitumor immunity to overcome relapse and improve remission duration.Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine.Inflammatory Signals Regulate IL-15 in Response to Lymphodepletion.Update on vaccine development for renal cell cancer.CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo Enhancing adoptive immunotherapy of cancer.IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use.Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.Advances in the development of cancer immunotherapies.Taming inflammation by targeting cytokine signaling: new perspectives in the induction of transplantation tolerance.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity.Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies.DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity.

P2860

Q21296718-586E383E-9F70-4A97-81B0-BACAE71FD499 Q26863283-70FC0D5B-11B7-4F4E-918D-66A0672998EC Q27014714-D80B0198-D098-49E4-AC93-8C026CC9E6AB Q27348572-3B436A4F-1795-4FD3-BFDD-F08B1682427F Q28072236-18F0CCE7-C79B-4DA6-8CEF-BB89440B608C Q28304923-FCCA7EA6-DB37-48D9-ABE0-973A8E72802E Q30300873-9A9AA35E-7189-4762-A356-FA5EFA288B59 Q30528191-D0E2942C-3DBA-4296-86C0-1F1055D96C8F Q33936084-6B7F7D17-EF81-4B1F-8661-5E481416AC1D Q33942539-E663CF9F-B8C5-4722-891B-A3AB4FD6BDD0 Q34117204-6DCE4C3F-AF27-4C75-B5BA-532CA4E19874 Q34257444-2192A6B4-0BF6-4E99-9432-254F4555C2EE Q34344946-3657C529-78C5-4754-B567-EC59F8C317F5 Q34353298-10E76B87-906E-4D44-8DB0-05E7BF94ED99 Q34494018-49E714D6-1947-4E88-AF58-E2CFFFD3E171 Q34557185-FD9D00A6-C9D9-4682-A14D-AA4BA13680B8 Q34634545-A6D35FB7-8DC5-411D-9C6F-C78207E74590 Q34748331-72A2DCCB-7152-4FA4-B43C-5D2E005F1F00 Q35346365-F181DCB7-C4DF-415F-868D-9CAC08893DF8 Q35574404-DF88AE1A-6D13-4509-BEFB-CD796B1B8892 Q36016455-E25E58A4-9C5F-41DF-8F71-B904FE2A5840 Q36044604-8EC75C48-A83C-476D-A118-7F68E52B8B48 Q36544143-71F5C6FA-70AE-46B2-8D09-A638B0EE993A Q36883892-00D41ED3-72D8-4B35-8DB5-0FD8A19E1124 Q36923600-5E450201-B426-472A-9BBA-00AE574300E9 Q36989720-61975CA8-82CC-4B7A-B492-105F82FFC77B Q37260574-C087170D-0B67-4C32-AF14-3CD995E459D4 Q37334596-0AE845AC-A16B-46A3-9C50-0839F586C0FD Q37386167-1D2F7D1C-A36F-43C2-A3A7-3B1E4D25EE93 Q37687429-83607630-D9EA-4B1B-8976-8A0876F53E34 Q37867104-E29A5B13-760E-49FD-90CA-6F7A1818D9B0 Q37991701-FAA223A4-7F2C-4D91-A1AD-BF10A1E365EF Q38025094-AB88E955-ED43-482C-863C-626A68A2E021 Q38049010-AA7A8405-2D45-4D1E-9EBD-007C6C66D094 Q38217596-B08C6588-0FDD-442E-82AE-026CC9DB028B Q38769021-282E165D-E457-4ED4-9060-466FEB1C126D Q40177753-F594B887-1D40-4AD1-A251-2E075966FE7A Q40248942-31451FE2-35D5-4072-9A54-D542ACA3A540 Q41826562-D5778C00-3154-4DF2-8DFF-9ABFB0FE3595 Q42208751-4EAA57EB-3907-48B8-A82D-F62C0CEE254B

P2860

IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity

http://www.wikidata.org/entity/Q37413874

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

IFN-alpha enhances peptide vac ...... nction, and antitumor activity

@en

IFN-alpha enhances peptide vac ...... ction, and antitumor activity.

@nl

type

label

IFN-alpha enhances peptide vac ...... nction, and antitumor activity

@en

IFN-alpha enhances peptide vac ...... ction, and antitumor activity.

@nl

prefLabel

IFN-alpha enhances peptide vac ...... nction, and antitumor activity

@en

IFN-alpha enhances peptide vac ...... ction, and antitumor activity.

@nl

P1433

Q37413874-852701D4-4CC7-4230-9547-6851455211C0

P1476

Q37413874-411D103A-2540-4CB9-8B6D-B6EC7BE1261E

P2093

Q37413874-149A521D-64E4-47B6-B4BA-A0A6285840FE

Q37413874-373E7253-1F0A-415D-95F0-BB7FA950C231

Q37413874-3A487013-9A63-487A-9264-A1431883A6F2

Q37413874-45C684CA-A8DD-464E-BBB4-32BBC3E2FA47

Q37413874-49624899-F630-42BA-93CA-7A7D7A3F84F0

Q37413874-8DF37EEB-A5BB-4FFB-8366-F77A9F601264

Q37413874-A830857C-66C0-416E-AC68-CD69F91968ED

Q37413874-ACBFF1CE-B131-47A3-B292-9F1A73B7189E

Q37413874-B6C868F9-3986-4590-9AF1-8F253A0637A9

Q37413874-C16B07D1-C8A8-4F6B-94BE-DC9123894181

P2860

Q37413874-0AFCD20F-031B-4552-89F3-AC90B2EBD0B1

Q37413874-0D73D30C-6A03-4310-A702-BF7152381C69

Q37413874-1098E4A1-8C85-477E-A202-74DBDE3483A4

Q37413874-14840324-ADED-4F72-8E52-03DF9B4CC6F2

Q37413874-27E05205-7911-4C2A-809E-FBAC752ABD02

Q37413874-2BA5092D-2D88-459E-B9D3-FE7BFA844C94

Q37413874-2D8C43AB-6A5E-4075-9651-80A9C233B90C

Q37413874-33B04B5A-9303-444B-874F-E15309B68D5F

Q37413874-36E92C9D-527E-4073-9902-D02F8CE95916

Q37413874-387BD697-F03F-45F9-AE15-835DC524B6F7

P304

Q37413874-3B10A814-EB86-4038-82EB-E94FC47A3CAE

P31

Q37413874-76E439CB-C880-46BC-9DEA-86DC02EA0986

P356

Q37413874-9BD94939-8D9E-4E89-8089-1D5B75CB5FA6

P407

Q37413874-49A469F0-C186-4980-93CC-726FBB0E009D

P433

Q37413874-59E29DCF-4ABE-456E-A521-3E0BE242962F

P478

Q37413874-E892AD10-0B62-434D-BB40-EBF99961E898

P577

Q37413874-F9FED2FB-F46B-4F11-B7DE-7036B356C343

P5875

Q37413874-08478D0E-B772-45D0-AF87-5042C24884A8

P698

Q37413874-CF5AD9C7-DA2F-4E17-B743-AED8B98AF6DE

P932

Q37413874-FC25E0F6-7258-4529-869B-837975DAE59A

P356

JIMMUNOL.0802982

P1433

Journal of Immunology

P1476

IFN-alpha enhances peptide vac ...... nction, and antitumor activity

@en

P2093

Alexander Gelbard

http://www.w3.org/2001/XMLSchema#string

Andrew G Sikora

http://www.w3.org/2001/XMLSchema#string

Chengwen Liu

http://www.w3.org/2001/XMLSchema#string

Helen A Andersson

http://www.w3.org/2001/XMLSchema#string

Kimberly S Schluns

http://www.w3.org/2001/XMLSchema#string

Loredana Frasca

http://www.w3.org/2001/XMLSchema#string

Nina Jaffarzad

http://www.w3.org/2001/XMLSchema#string

Patrick Hwu

http://www.w3.org/2001/XMLSchema#string

Spencer W Stonier

http://www.w3.org/2001/XMLSchema#string

Willem W Overwijk

http://www.w3.org/2001/XMLSchema#string

P2860

Functional role of type I and type II interferons in antiviral defense

Cancer immunotherapy: moving beyond current vaccines

IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation

Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus

The roles of interleukin-15 receptor alpha: trans-presentation, receptor component, or both?

Macrophage inflammatory protein-1

Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection

Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice

Type I interferons in host defense

Recognition of microorganisms and activation of the immune response

P304

7398-7407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.0802982

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26264668

http://www.w3.org/2001/XMLSchema#string

P698

19494262

http://www.w3.org/2001/XMLSchema#string

P932

2774140

http://www.w3.org/2001/XMLSchema#string